神经科

订阅

MedSci主页 / 所有栏目 / 神经科

Teva旗下偏头痛预防性药物Ajovy获得FDA批准

2018-09-17 MedSci MedSci原创

Ajovy偏头痛Teva
关注

Teva制药公司近日宣布，FDA已经正式批准了Ajovy（fremanezumab-vfrm）注射剂，Ajovy因此成为第一个用于预防成人偏头痛的长效抗CGRP药物（按月度和季度给药）。Teva全球研发执行副总裁Hafrun Fridriksdottir说：“由于偏头痛的预防性治疗选择有限，Ajovy能为医生提供一个重要的新选择。这项批准进一步促进了我们在偏头痛等神经系统疾病方面的持续创新”。

Teva制药公司近日宣布，FDA已经正式批准了Ajovy（fremanezumab-vfrm）注射剂，Ajovy因此成为第一个用于预防成人偏头痛的长效抗CGRP药物（按月度和季度给药）。Teva全球研发执行副总裁Hafrun Fridriksdottir说：“由于偏头痛的预防性治疗选择有限，Ajovy能为医生提供一个重要的新选择。这项批准进一步促进了我们在偏头痛等神经系统疾病方面的持续创新”。

偏头痛多为一侧或两侧颞部反复发作的搏动性头痛，发作前可伴视觉、体觉先兆，发作时常伴呕吐。女性多发，约为男性的3-4倍，多在青春期起病，发病年龄25-34岁，少数发生于儿童期或中年后。Teva表示，大约两周内将通过美国零售和专业药店提供Ajovy。Ajovy在美国的售价约为每月575美元，每季度1725美元。该公司指出，部分商品保险患者可以免费获得Ajovy，Teva在北美的商业运营负责人Brendan O’Grady表示，其很自豪能够以负责任的价格推出这种新的生物制品，并渴望与保险公司合作，鼓励保险公司将Ajovy完全纳入报销范围”。


原始出处：

http://www.firstwordpharma.com/node/1591344?tsid=28®ion_id=2#axzz5RMgX4mDX

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1704824, encodeId=c5af1e04824d5, content=<a href='/topic/show?id=7b952225aa' target=_blank style='color:#2F92EE;'>#Ajovy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2225, encryptionId=7b952225aa, topicName=Ajovy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65d30842306, createdName=longerg, createdTime=Wed Feb 13 23:31:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034794, encodeId=aa9f2034e9422, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jul 29 09:31:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839622, encodeId=222e1839622fb, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 21 21:31:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345399, encodeId=f7e63453994a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Sep 17 22:28:44 CST 2018, time=2018-09-17, status=1, ipAttribution=)]
    2019-02-13 longerg

    #Ajovy#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1704824, encodeId=c5af1e04824d5, content=<a href='/topic/show?id=7b952225aa' target=_blank style='color:#2F92EE;'>#Ajovy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2225, encryptionId=7b952225aa, topicName=Ajovy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65d30842306, createdName=longerg, createdTime=Wed Feb 13 23:31:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034794, encodeId=aa9f2034e9422, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jul 29 09:31:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839622, encodeId=222e1839622fb, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 21 21:31:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345399, encodeId=f7e63453994a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Sep 17 22:28:44 CST 2018, time=2018-09-17, status=1, ipAttribution=)]
    2019-07-29 839640778

    #预防性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1704824, encodeId=c5af1e04824d5, content=<a href='/topic/show?id=7b952225aa' target=_blank style='color:#2F92EE;'>#Ajovy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2225, encryptionId=7b952225aa, topicName=Ajovy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65d30842306, createdName=longerg, createdTime=Wed Feb 13 23:31:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034794, encodeId=aa9f2034e9422, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jul 29 09:31:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839622, encodeId=222e1839622fb, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 21 21:31:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345399, encodeId=f7e63453994a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Sep 17 22:28:44 CST 2018, time=2018-09-17, status=1, ipAttribution=)]
    2018-09-21 智者为医08

    #FDA批准#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1704824, encodeId=c5af1e04824d5, content=<a href='/topic/show?id=7b952225aa' target=_blank style='color:#2F92EE;'>#Ajovy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2225, encryptionId=7b952225aa, topicName=Ajovy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65d30842306, createdName=longerg, createdTime=Wed Feb 13 23:31:00 CST 2019, time=2019-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034794, encodeId=aa9f2034e9422, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Jul 29 09:31:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839622, encodeId=222e1839622fb, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 21 21:31:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345399, encodeId=f7e63453994a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Sep 17 22:28:44 CST 2018, time=2018-09-17, status=1, ipAttribution=)]
    2018-09-17 医者仁心5538

    学习了

    0